Lansoprazole Patent Expiration

Lansoprazole is a drug owned by Dexcel Pharma Technologies Ltd. It is protected by 2 US drug patents filed from 2021 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 21, 2036. Details of Lansoprazole's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077055 Orally disintegrating compositions
Apr, 2036

(11 years from now)

Active
US11986554 Orally disintegrating compositions
Apr, 2036

(11 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lansoprazole's patents.

Given below is the list of recent legal activities going on the following patents of Lansoprazole.

Activity Date Patent Number
Patent litigations
Patent Issue Date Used in PTA Calculation 03 Aug, 2021 US11077055
Recordation of Patent Grant Mailed 03 Aug, 2021 US11077055
Email Notification 15 Jul, 2021 US11077055
Issue Notification Mailed 14 Jul, 2021 US11077055
Dispatch to FDC 28 Jun, 2021 US11077055
Application Is Considered Ready for Issue 28 Jun, 2021 US11077055
Issue Fee Payment Verified 23 Jun, 2021 US11077055
Issue Fee Payment Received 23 Jun, 2021 US11077055
Electronic Review 19 Jun, 2021 US11077055
Email Notification 18 Jun, 2021 US11077055

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Lansoprazole is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lansoprazole's family patents as well as insights into ongoing legal events on those patents.

Lansoprazole's Family Patents

Lansoprazole has patent protection in a total of 3 countries. It has a significant patent presence in the US with 57.1% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Lansoprazole.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Lansoprazole's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 21, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Lansoprazole Generics:

Lansoprazole is the generic name for the brand Lansoprazole. 26 different companies have already filed for the generic of Lansoprazole, with Mylan having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lansoprazole's generic

Alternative Brands for Lansoprazole

There are several other brand drugs using the same active ingredient (Lansoprazole) as Lansoprazole. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Takeda Pharms Na
Prevacid Iv
Takeda Pharms Usa
Dexilant
Dexilant Solutab
Prevacid


Apart from brand drugs containing the same ingredient, some generics have also been filed for Lansoprazole, Lansoprazole's active ingredient. Check the complete list of approved generic manufacturers for Lansoprazole





About Lansoprazole

Lansoprazole is a drug owned by Dexcel Pharma Technologies Ltd. Lansoprazole uses Lansoprazole as an active ingredient. Lansoprazole was launched by Dexcel in 2016.

Approval Date:

Lansoprazole was approved by FDA for market use on 07 June, 2016.

Active Ingredient:

Lansoprazole uses Lansoprazole as the active ingredient. Check out other Drugs and Companies using Lansoprazole ingredient

Dosage:

Lansoprazole is available in tablet, orally disintegrating, delayed release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
15MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE Over the counter ORAL